Telomere attrition as a hallmark of aging: telomere mechanism

Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase expression is low in many differentiated normal tissues, while some normal proliferating cells can express it. Cancer can also use telomere maintenance; the included human records do not resolve long-term cancer risk from pharmacological activation. Tellingly, the FDA-approved telomerase inhibitor — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.

Definition

Category: Causal-framing concept

Also known as: telomere shortening, hallmark of aging

Telomere attrition is included in the Hallmarks of Aging framework. Telomeres can shorten with division in the absence of sufficient telomere maintenance, and critically dysfunctional telomeres can trigger growth arrest or cell death. Cell type, telomerase activity and stress context matter. Changing a telomere-length measurement in a trial does not establish an effect on human aging.

Key points

The hallmark framing is associative and mechanistic; it is not proof that lengthening telomeres in humans slows aging or extends lifespan.
Telomere length is a contested aging biomarker: it is measured differently by different methods, varies between tissues, and 'longer' is not straightforwardly 'healthier'.
This causal-framing page exists so that every intervention page can be read against the honest gap between 'changed a telomere number' and 'slowed human aging'.
Telomere-driven replicative senescence links this cluster to senesiq.com, which is cross-referenced rather than duplicated.

Sourcing

Synthesis of standard aging-biology reviews (Lopez-Otin et al. Hallmarks of Aging; Blasco telomere reviews). Review-level, not a primary numeric claim.

Reference synthesis (mechanism context, not a human-trial evidence tier).